Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification

• Published in: European journal of surgical oncology 2023-09, Vol.49 (9), p.106910-106910, Article 106910
• Main Authors: van Oosten, A. Floortje, Daamen, Lois A., Groot, Vincent P., Biesma, Nanske C., Habib, Joseph R., van Goor, Iris W.J.M., Kinny-Köster, Benedict, Burkhart, Richard A., Wolfgang, Christopher L., van Santvoort, Hjalmar C., He, Jin, Molenaar, I. Quintus
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Pancreatic Ductal - pathology; Humans; Neoplasm Recurrence, Local - pathology; Pancreatectomy - methods; Pancreatic ductal adenocarcinoma; Pancreatic Neoplasms; Pancreatic Neoplasms - pathology; Post-recurrence survival; Prognosis; Recurrence; Retrospective Studies; Risk score; Survival after recurrence
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2023.04.009

Over 80% of patients will develop disease recurrence after radical resection of pancreatic ductal adenocarcinoma (PDAC). This study aims to develop and validate a clinical risk score predicting post-recurrence survival (PRS) at time of recurrence. All patients who had recurrence after undergoing pancreatectomy for PDAC at the Johns Hopkins Hospital or at the Regional Academic Cancer Center Utrecht during the study period were included. Cox proportional hazard model was used to develop the risk model. Performance of the final model was assessed in a test set after internal validation. Of 718 resected PDAC patients, 72% had recurrence after a median follow-up of 32 months. The median overall survival was 21 months and the median PRS was 9 months. Prognostic factors associated with shorter PRS were age (hazard ratio [HR] 1.02; 95% confidence interval [95%CI] 1.00–1.04), multiple-site recurrence (HR 1.57; 95%CI 1.08–2.28), and symptoms at time of recurrence (HR 2.33; 95%CI 1.59–3.41). Recurrence-free survival longer than 12 months (HR 0.55; 95%CI 0.36–0.83), FOLFIRINOX and gemcitabine-based adjuvant chemotherapy (HR 0.45; 95%CI 0.25–0.81; HR 0.58; 95%CI 0.26–0.93, respectively) were associated with a longer PRS. The resulting risk score had a good predictive accuracy (C-index: 0.73). This study developed a clinical risk score based on an international cohort that predicts PRS in patients who underwent surgical resection for PDAC. This risk score will become available on www.evidencio.com and can help clinicians with patient counseling on prognosis. SYNOPSIS.This study developed a risk score that predicts post-recurrence survival in patients who underwent surgical resection for pancreatic ductal adenocarcinoma. This score will become available on www.evidencio.com and can help clinicians with patient counseling on prognosis and shared decision-making.